It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner Forest Laboratories Inc., the oral dopamine D3 selective D3/D2 receptor agonist Capriprazine (RGH-188) significantly improved symptoms in 497 patients with acute mania episodes, according to the Young Mania Rating Scale. In the same week, Gedeon Richter’s Swiss subsidiary PregLem SA published positive results from two Phase III studies with Esmya (ulipristal) in NEJM (2012; 366: 409-420, 421-432). The progesterone receptor modulator, which is to receive EU market approval soon, significantly improved symptoms of uterine fibroids (myomas).